Straube, Sebastian

[["dc.bibliographiccitation.artnumber","CD008183"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Wiffen, Phillip J."],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:23Z"],["dc.date.available","2018-11-07T08:47:23Z"],["dc.date.issued","2010"],["dc.description.abstract","Background Gabapentin is an antiepileptic drug, also used in the treatment of neuropathic pain, which is the subject of a Cochrane review, currently under revision. Its efficacy in treating established acute postoperative pain has not been demonstrated. Objectives To assess the efficacy and safety of single dose oral gabapentin compared with placebo in established acute postoperative pain using methods that permit comparison with other analgesics. Search strategy We searched Cochrane CENTRAL, MEDLINE, EMBASE, and the Oxford Pain Relief Database. Additional studies were sought from reference lists of retrieved articles and reviews. Clinical trials databases were searched for unpublished studies; clinical trial reports of several unpublished studies have been made public following litigation in the US. Selection criteria Single oral dose, randomised, double-blind, placebo-controlled trials of gabapentin for relief of established moderate to severe postoperative pain in adults. Data collection and analysis Studies were assessed for methodological quality and data extracted by two review authors independently. Numbers of participants with at least 50% of maximum possible total pain relief (TOTPAR) or summed pain intensity difference (SPID) with gabapentin or placebo were calculated and used to derive relative benefit (RB) or risk (RR), and number-needed-to-treat-to-benefit (NNT). Numbers of participants using rescue medication, and time to its use, were sought as additional measures of efficacy. Information on adverse events and withdrawals was collected. Main results Four unpublished studies met inclusion criteria; in three, participants had pain following dental surgery, and one followed major orthopaedic surgery; 177 participants were treated with a single dose of gabapentin 250 mg, 21 with gabapentin 500 mg, and 172 with placebo. At least 50% pain relief over 6 hours was achieved by 15% with gabapentin 250 mg and 5% with placebo; giving a RB of 2.5 (95% CI 1.2 to 5.0) and an NNT of 11 (6.4 to 35). Significantly fewer participants needed rescue medication within 6 hours with gabapentin 250 mg than with placebo; NNT to prevent use 5.8. About one third of participants reported adverse events with both gabapentin 250 mg and placebo. No serious adverse events occurred with gabapentin. Authors' conclusions Gabapentin 250 mg is statistically superior to placebo in the treatment of established acute postoperative pain, but the NNT of 11 for at least 50% pain relief over 6 hours with gabapentin 250 mg is of limited clinical value and inferior to commonly used analgesics. Gabapentin 250 mg is not clinically useful as a stand-alone analgesic in established acute postoperative pain, though this is probably the first demonstration of analgesic effect of an antiepileptic in established acute pain."],["dc.description.sponsorship","NHS; NIHR; Oxford Pain Research Funds"],["dc.identifier.doi","10.1002/14651858.CD008183.pub2"],["dc.identifier.isi","000277611100029"],["dc.identifier.pmid","20464764"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6214"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20937"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Single dose oral gabapentin for established acute postoperative pain in adults"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD007771"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:24Z"],["dc.date.available","2018-11-07T08:47:24Z"],["dc.date.issued","2010"],["dc.description.abstract","Background Vitamin D is produced in the skin after sun-light exposure and can also be obtained through food. Vitamin D deficiency has recently been linked with a range of diseases including chronic pain. Observational and circumstantial evidence suggests that there may be a role for vitamin D deficiency in the aetiology of chronic pain conditions. Objectives To assess the efficacy and adverse events of vitamin D supplementation in chronic painful conditions. Search strategy We searched Cochrane CENTRAL, MEDLINE, EMBASE and the Oxford Pain Relief Database for studies to September 2009. This was supplemented by searching the reference lists of retrieved articles, textbooks and reviews. Selection criteria Studies were included if they were randomised double blind trials of vitamin D supplementation compared with placebo or with active comparators for the treatment of chronic pain conditions in adults. Data collection and analysis Two review authors independently selected the studies for inclusion, assessed methodological quality, and extracted data. Pooled analysis was not undertaken due to paucity and heterogeneity of data. Main results Four studies, with a total of 294 participants, were included. The studies were heterogeneous with regard to study quality, the chronic painful conditions that were investigated, and the outcome measures reported. Only one study reported a beneficial effect, the others found no benefit of vitamin D over placebo in treating chronic pain. Authors' conclusions The evidence base for the use of vitamin D for chronic pain in adults is poor at present. This is due to low quality and insufficient randomised controlled trials in this area of research."],["dc.description.sponsorship","NHS Cochrane Collaboration UK; NIHR"],["dc.identifier.doi","10.1002/14651858.CD007771.pub2"],["dc.identifier.isi","000274653900040"],["dc.identifier.pmid","20091647"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20938"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Vitamin D for the treatment of chronic painful conditions in adults"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","150"],["dc.bibliographiccitation.journal","BMC Musculoskeletal Disorders"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Paine, Jocelyn"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:41:25Z"],["dc.date.available","2018-11-07T08:41:25Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Population mean changes are difficult to use in clinical practice. Responder analysis may be better, but needs validating for level of response and treatment duration. A consensus group has defined what constitutes minimal, moderate, and substantial benefit based on pain intensity and Patient Global Impression of Change scores. Methods: We obtained individual patient data from four randomised double blind trials of pregabalin in fibromyalgia lasting eight to 14 weeks. We calculated response for all efficacy outcomes using any improvement (>= 0%), minimal improvement (>= 15%), moderate improvement (>= 30%), substantial improvement (>= 50%), and extensive improvement (>= 70%), with numbers needed to treat (NNT) for pregabalin 300 mg, 450 mg, and 600 mg daily compared with placebo. Results: Information from 2,757 patients was available. Pain intensity and sleep interference showed reductions with increasing level of response, a significant difference between pregabalin and placebo, and a trend towards lower (better) NNTs at higher doses. Maximum response rates occurred at 4-6 weeks for higher levels of response, and were constant thereafter. NNTs (with 95% confidence intervals) for >= 50% improvement in pain intensity compared with placebo after 12 weeks were 22 (11 to 870) for pregabalin 300 mg, 16 (9.3 to 59) for pregabalin 450 mg, and 13 (8.1 to 31) for pregabalin 600 mg daily. NNTs for >= 50% improvement in sleep interference compared with placebo after 12 weeks were 13 (8.2 to 30) for pregabalin 300 mg, 8.4 (6.0 to 14) for pregabalin 450 mg, and 8.4 (6.1 to 14) for pregabalin 600 mg. Other outcomes had fewer respondents at higher response levels, but generally did not discriminate between pregabalin and placebo, or show any dose response. Shorter duration and use of 'any improvement' over-estimated treatment effect compared with longer duration and higher levels of response. Conclusions: Responder analysis is useful in fibromyalgia, particularly for pain and sleep outcomes. Some fibromyalgia patients treated with pregabalin experience a moderate or substantial pain response that is consistent over time. Short trials using 'any improvement' as an outcome overestimate treatment effects."],["dc.description.sponsorship","Pfizer Inc.; Oxford Pain Relief Trust; NIHR Biomedical Research Centre"],["dc.identifier.doi","10.1186/1471-2474-11-150"],["dc.identifier.isi","000280833800005"],["dc.identifier.pmid","20602781"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5670"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19464"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2474"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Pregabalin in fibromyalgia - responder analysis from individual patient data"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","41"],["dc.bibliographiccitation.journal","BMC Gastroenterology"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Tramer, Martin R."],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:28:47Z"],["dc.date.available","2018-11-07T08:28:47Z"],["dc.date.issued","2009"],["dc.description.abstract","Background: Some people who suffer an upper gastrointestinal bleed or perforation die. The mortality rate was estimated at 12% in studies published before 1997, but a systematic survey of more recent data is needed. Better treatment is likely to have reduced mortality. An estimate of mortality is helpful in explaining to patients the risks of therapy, especially with NSAIDs. Methods: A systematic review of studies published before 1997, and between 1997 and 2008. Any study architecture was acceptable if it reported on cases who died from any cause of upper gastrointestinal bleed or perforation. Analyses were conducted separately for all cases, and those prescribed NSAID or aspirin. Results: Information was available for 61,067 cases (81% published since 1997) of whom 5,001 died. The mortality rate in all cases fell significantly, from 11.6% (95% confidence interval, 11.0 to 12.2) in pre-1997 studies to 7.4% (7.2 to 7.6) in those published since 1997. In 5,526 patients taking NSAID or aspirin, mortality increased, from 14.7% (13.6 to 15.8) before 1997 to 20.9% (18.8 to 22.9) since 1997. Conclusion: Upper gastrointestinal bleed or perforation still carries a finite risk of death. Differences in study architecture, population characteristics, risk factors, definition of mortality, and reporting of outcomes impose limitations on interpreting effect size. Data published since 1997 suggest that mortality in patients suffering from an upper gastrointestinal bleed or perforation has fallen to 1 in 13 overall, but remains higher at about 1 in 5 in those exposed to NSAID or aspirin."],["dc.description.sponsorship","Oxford Pain Research Trust"],["dc.identifier.doi","10.1186/1471-230X-9-41"],["dc.identifier.isi","000267760400001"],["dc.identifier.pmid","19500343"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5799"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16502"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-230X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","CD002918"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","COCHRANE DATABASE OF SYSTEMATIC REVIEWS"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:23Z"],["dc.date.available","2018-11-07T08:47:23Z"],["dc.date.issued","2010"],["dc.description.abstract","Background This review is an update on 'Sympathectomy for neuropathic pain' originally published in Issue 2, 2003. The concept that many neuropathic pain syndromes (traditionally this definition would include complex regional pain syndromes (CRPS)) are \"sympathetically maintained pains\" has historically led to treatments that interrupt the sympathetic nervous system. Chemical sympathectomies use alcohol or phenol injections to destroy ganglia of the sympathetic chain, while surgical ablation is performed by open removal or electrocoagulation of the sympathetic chain, or minimally invasive procedures using thermal or laser interruption. Objectives To review the evidence from randomised, double blind, controlled trials on the efficacy and safety of chemical and surgical sympathectomy for neuropathic pain. Sympathectomy could be compared with placebo (sham) or other active treatment. Search strategy We searched MEDLINE, EMBASE and The Cochrane Library to May 2010. We screened references in the retrieved articles and literature reviews, and contacted experts in the field of neuropathic pain. Selection criteria Randomised, double blind, placebo or active controlled studies assessing the effects of sympathectomy for neuropathic pain and CRPS. Data collection and analysis Two review authors independently assessed trial quality and validity, and extracted data. No pooled analysis of data was possible. Main results Only one study satisfied our inclusion criteria, comparing percutaneous radiofrequency thermal lumbar sympathectomy with lumbar sympathetic neurolysis using phenol in 20 participants with CRPS. There was no comparison of sympathectomy versus shamor placebo. No dichotomous pain outcomes were reported. Average baseline scores of 8-9/10 on several pain scales fell to about 4/10 initially (1 day) and remained at 3-5/10 over four months. There were no significant differences between groups, except for \"unpleasant sensation\",which was higher with radiofrequency ablation. One participant in the phenol group experienced postsympathectomy neuralgia, while two in the radiofrequency group and one in the phenol group complained of paresthaesia during needle positioning. All participants had soreness at the injection site. Authors' conclusions The practice of surgical and chemical sympathectomy for neuropathic pain and CRPS is based on very little high quality evidence. Sympathectomy should be used cautiously in clinical practice, in carefully selected patients, and probably only after failure of other treatment options."],["dc.description.sponsorship","Department of Health [HTA/93/31/04]"],["dc.identifier.doi","10.1002/14651858.CD002918.pub2"],["dc.identifier.isi","000279630900032"],["dc.identifier.pmid","20614432"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6212"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20934"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","John Wiley & Sons Ltd"],["dc.relation.issn","1469-493X"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","125"],["dc.bibliographiccitation.journal","BMC Musculoskeletal Disorders"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Paine, Jocelyn"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Phillips, Ceri J."],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:55:09Z"],["dc.date.available","2018-11-07T08:55:09Z"],["dc.date.issued","2011"],["dc.description.abstract","Background: Clinical trials in chronic pain often collect information about interference with work as answers to component questions of commonly used questionnaires but these data are not normally analysed separately. Methods: We performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks. We analysed data on interference with work, inferred from answers to component questions of Fibromyalgia Impact Questionnaire (FIQ), Short Form 36 Health Survey, Sheehan Disability Scale, and Multidimensional Assessment of Fatigue, including \"How many days in the past week did you miss work, including housework, because of fibromyalgia?\" from FIQ. Analyses were performed according to randomised treatment group (pregabalin 150-600 mg daily or placebo), pain improvement (0-10 numerical pain rating scale scores at trial beginning vs. end), and end of trial pain state (100 mm visual analogue pain scale [VAS]). Results: Comparing treatment group average outcomes revealed modest improvement over the duration of the trials, more so with active treatment than with placebo. For the 'work missed' question from FIQ the change for patients on placebo was from 2.2 (standard deviation [SD] 2.3) days of work lost per week at trial beginning to 1.9 (SD 2.1) days lost at trial end (p < 0.01). For patients on 600 mg pregabalin the change was from 2.1 (SD 2.2) days to 1.6 (SD 2.0) days (p < 0.001). However, the change in days of work lost was substantial in patients with a good pain response: from 2.0 (SD 2.2) days to 0.97 (SD 1.6) days (p < 0.0001) for those experiencing >/= 50% pain improvement and from 1.9 (SD 2.2) days to 0.73 (SD 1.4) days (p < 0.0001) for those achieving a low level of pain at trial end (< 30 mm on the VAS). Patients achieving both >/= 50% pain improvement and a pain score < 30 mm on the VAS had the largest improvement, from 2.0 (SD 2.2) days to 0.60 (SD 1.3) days (p < 0.0001). Analysing answers to the other questions yielded qualitatively similar results. Conclusions: Effective pain treatment goes along with benefit regarding work. A reduction in time off work > 1 day per week can be achieved in patients with good pain responses."],["dc.identifier.doi","10.1186/1471-2474-12-125"],["dc.identifier.isi","000291748700002"],["dc.identifier.pmid","21639874"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/6374"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22838"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2474"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Interference with work in fibromyalgia - effect of treatment with pregabalin and relation to pain response"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","753075"],["dc.bibliographiccitation.journal","International Journal of Endocrinology"],["dc.contributor.author","Straube, Sebastian"],["dc.contributor.author","Moore, R. Andrew"],["dc.contributor.author","Derry, Sheena"],["dc.contributor.author","Hallier, Ernst"],["dc.contributor.author","McQuay, Henry J."],["dc.date.accessioned","2018-11-07T08:47:49Z"],["dc.date.available","2018-11-07T08:47:49Z"],["dc.date.issued","2010"],["dc.description.abstract","Vitamin D deficiency has been implicated in chronic pain. Immigrant and ethnic minority populations have been shown to have lower vitamin D levels than native Western populations and often to be vitamin D deficient. This systematic review investigates the relationship between vitamin D and chronic pain in immigrant and ethnic minority populations. Included were studies reporting on 25-OH vitamin D levels in immigrant/ethnic minority populations affected by chronic pain, and/or reporting on the treatment of chronic pain with vitamin D preparations in such populations. We found that 25-OH vitamin D levels were low and often deficient in immigrant/ethnic minority populations. Vitamin D levels depended on the latitude of the study location and hence sunlight exposure. There was insufficient evidence to reach a verdict on the value of treating chronic pain in immigrant/ethnic minority patients with vitamin D preparations because the studies were few, small, and of low quality."],["dc.description.sponsorship","Oxford Pain Research Trust; NIHR Biomedical Research Centre"],["dc.identifier.doi","10.1155/2010/753075"],["dc.identifier.isi","000284937800001"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5904"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21057"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Hindawi Publishing Corporation"],["dc.relation.issn","1687-8337"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Vitamin D and Chronic Pain in Immigrant and Ethnic Minority Patients-Investigation of the Relationship and Comparison with Native Western Populations"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]